Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin tablets for discoid lupus erythematosus
ChiCTR2600124305Phase 2Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- May 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dihydroartemisinin in discoid lupus erythematosus (DLE) (3 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Percentage change from baseline in CLASI-A score at week 24. Planned start May 2026; status: not yet recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on ChiCTR2600124305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124305.